Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

6.2K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.2K
Cancer Therapies02:49

Cancer Therapies

10.3K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
10.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Angiosarcoma masquerading as popliteal artery aneurysm.

VASA. Zeitschrift fur Gefasskrankheiten·2026
Same author

Editorial Expression of Concern: Rationale for co-targeting IGF-1R and ALK in ALK fusion-positive lung cancer.

Nature medicine·2025
Same author

Twenty years of human bocavirus research: from an unculturable virus of unclear pathogenicity to a culturable human pathogen and gene therapy vector candidate.

Clinical microbiology reviews·2025
Same author

Learning microbiology and virology from the cinema.

Journal of microbiology & biology education·2025
Same author

T84 Monolayer Cell Cultures Support Productive HBoV and HSV-1 Replication and Enable In Vitro Co-Infection Studies.

Viruses·2024
Same author

Evolutionary trajectories of small cell lung cancer under therapy.

Nature·2024

Related Experiment Video

Updated: Feb 26, 2026

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.8K

Cost Saving Opportunities in NSCLC Therapy by Optimized Diagnostics.

Ilija Nenadić1, Jeanine Staber2, Susanne Dreier3

  • 1Kliniken der Stadt Köln gGmbH, Klinikum der Privaten Universität Witten/Herdecke mit Sitz in Köln, Institut für Pathologie, D-51109 Cologne, Germany. nenadici@kliniken-koeln.de.

Cancers
|July 12, 2017
PubMed
Summary

Anaplastic lymphoma kinase (ALK) mutations in non-small-cell lung cancer (NSCLC) have variable treatment outcomes. Novel diagnostic tools and predictive models could improve therapy and reduce healthcare costs.

Keywords:
ALKNSCLCcost savingcrizotiniblung cancer

More Related Videos

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing
05:17

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing

Published on: October 10, 2025

472
Comprehensive & Cost Effective Laboratory Monitoring of HIV/AIDS: an African Role Model
23:56

Comprehensive & Cost Effective Laboratory Monitoring of HIV/AIDS: an African Role Model

Published on: October 31, 2010

17.3K

Related Experiment Videos

Last Updated: Feb 26, 2026

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.8K
Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing
05:17

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing

Published on: October 10, 2025

472
Comprehensive & Cost Effective Laboratory Monitoring of HIV/AIDS: an African Role Model
23:56

Comprehensive & Cost Effective Laboratory Monitoring of HIV/AIDS: an African Role Model

Published on: October 31, 2010

17.3K

Area of Science:

  • Oncology
  • Genetics
  • Pharmacology

Background:

  • Non-small-cell lung cancer (NSCLC) affects up to 350,000 individuals annually in the EU.
  • Anaplastic lymphoma kinase (ALK) inhibitors offer targeted therapy for up to 10% of NSCLC patients with specific ALK mutations.
  • Current ALK diagnostics (FISH) and therapies (Crizotinib) show variable efficacy, with potential misdiagnosis rates up to 10%.

Purpose of the Study:

  • To investigate the association between diverse ALK mutations and variable treatment success in NSCLC.
  • To evaluate the potential of novel companion diagnostics and therapy outcome prediction models.
  • To explore cost-saving opportunities in European healthcare systems for ALK-targeted NSCLC treatment.

Main Methods:

  • Analysis of ALK mutation prevalence and therapy outcomes in a German NSCLC patient cohort.
  • Review of existing literature on ALK fusion variants, their biological activity, and sensitivity to Crizotinib.
  • Assessment of current diagnostic procedures, including Fluorescent in situ Hybridization (FISH).

Main Results:

  • Significant variability in treatment response to ALK inhibitors observed, linked to a wide spectrum of ALK mutations and variants.
  • Limited understanding of the biological function and clinical relevance of all known ALK fusion variants.
  • Potential for misdiagnosis and suboptimal treatment due to limitations in current diagnostic methods.

Conclusions:

  • The heterogeneity of ALK mutations necessitates advanced diagnostic approaches beyond current FISH assays.
  • Developing predictive models for therapy outcomes can optimize Crizotinib treatment and patient care.
  • Implementing novel companion diagnostics and predictive tools may lead to substantial cost savings in NSCLC management.